Table 4.
Effects of peptide treatments on the CL4176 paralysis and statistical analyses of the paralysis curves a.
| Treatment | Dose | Trial | Strain | Nematodes (n) | Onset Paralysis b | Paralyzed Worms c | Log Rank Χ2 | p-Value |
|---|---|---|---|---|---|---|---|---|
| PACEI50L | 0.5 | 1 | NGM | 110 | 41 (98.2%) | 70.0% | ||
| NGM + PACEI50L | 92 | 45 (96.7%) | 41.3% | 16.65 | <0.0001 | |||
| 2 | NGM | 113 | 43 (94.7%) | 68.1% | ||||
| NGM + PACEI50L | 120 | 43 (99.2%) | 41.7% | 16.94 | <0.0001 | |||
| 0.1 | 1 | NGM | 181 | 43 (96.1%) | 68.5% | |||
| NGM + PACEI50L | 189 | 41 (98.4%) | 48.7% | 15.24 | <0.0001 | |||
| 2 | NGM | 113 | 43 (94.7%) | 68.1% | ||||
| NGM + PACEI50L | 105 | 43 (99.1%) | 21.9% | 40.92 | <0.0001 | |||
| 3 | NGM | 102 | 41 (95.1%) | 65.7% | ||||
| NGM + PACEI50L | 80 | 43 (97.5%) | 56.2% | 4.386 | 0.0362 | |||
| PKH11 | 0.5 | 1 | NGM | 110 | 41 (98.2%) | 70.0% | ||
| NGM + PKH11 | 127 | 43 (96.9%) | 59.1% | 3.845 | 0.0499 | |||
| 2 | NGM | 113 | 43 (94.7%) | 68.1% | ||||
| NGM + PKH11 | 109 | 43 (97.2%) | 55.1% | 5.692 | 0.0170 | |||
| 0.1 | 1 | NGM | 113 | 41 (98.2%) | 68.8% | |||
| NGM + PKH11 | 110 | 43 (98.2%) | 32.7% | 7.643 | 0.0057 | |||
| 2 | NGM | 113 | 43 (94.7%) | 68.1% | ||||
| NGM + PKH11 | 123 | 43 (99.2%) | 30.9% | 32.09 | <0.0001 | |||
| 3 | NGM | 106 | 41 (98.1%) | 76.6% | ||||
| NGM + PKH11 | 102 | 43 (95.1%) | 64.7% | 32.71 | <0.0001 | |||
| 4 | NGM | 104 | 41 (98.1%) | 76.6% | ||||
| NGM + PKH11 | 99 | 43 (98.0%) | 61.6% | 39.88 | <0.0001 | |||
| PACEI50L-v1 | 0.1 | 1 | NGM | 181 | 43 (96.1%) | 68.5% | ||
| NGM + PACEI50L-v1 | 200 | 41 (98.0%) | 62.5% | 0.5108 | 0.4748 | |||
| 2 | NGM | 102 | 41 (95.1%) | 65.7% | ||||
| NGM + PACEI50L-v1 | 121 | 41 (91.7%) | 71.9% | 1.7 × 10−7 | 0.9997 | |||
| 3 | NGM | 113 | 41 (98.2%) | 48.7% | ||||
| NGM + PACEI50L-v1 | 134 | 41 (93.3%) | 53.7% | 0.5045 | 0.4775 | |||
| PACEI50L-v2 | 0.1 | 1 | NGM | 181 | 43 (96.1%) | 68.5% | ||
| NGM + PACEI50L-v2 | 195 | 41 (91.3%) | 74.9% | 7.489 | 0.0062 | |||
| 2 | NGM | 102 | 41 (95.1%) | 65.7% | ||||
| NGM + PACEI50L-v2 | 108 | 41 (90.7%) | 75.9% | 0.0979 | 0.7543 | |||
| 3 | NGM | 113 | 41 (98.2%) | 68.8% | ||||
| NGM + PACEI50L-v2 | 114 | 41 (94.7%) | 68.4% | 7.296 | 0.0069 | |||
| PKH11-v1 | 0.1 | 1 | NGM | 106 | 41 (98.1%) | 76.6% | ||
| NGM + PKH11-v1 | 100 | 43 (98.0%) | 52.0% | 42.14 | <0.0001 | |||
| 2 | NGM | 104 | 41 (98.1%) | 76.6% | ||||
| NGM + PKH11-v1 | 100 | 43 (98.9%) | 64.0% | 23.16 | <0.0001 |
a Analyses were performed with a paired log Rank survival test (survival curves are significantly different with respect to nematode growth medium (NGM) when p < 0.05). b Time (hours) of onset paralysis and % of non-paralyzed worms in brackets. c Percentage of paralyzed worms at 49 h.